Obigen Pharma

Obigen Pharma EPS

The Earnings per Share (EPS) of Obigen Pharma (7876.TWO) as of Oct 16, 2026 is -2.57 TWD. In the previous year, Earnings per Share (EPS) was -2.29 TWD — a change of 11.83% (lower).

EPS

-2.57TWD

YoY

11.83%

Last updated:

Earnings per Share (EPS) of Obigen Pharma is 2024 -2.57 TWD. Earnings per Share (EPS) of Obigen Pharma was 2023 -2.29 TWD. It decreases by 11.83% lower compared to the previous year.

The Obigen Pharma EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-2.04 TWD
Jan 1, 2023
-2.29 TWD
Jan 1, 2024
-2.57 TWD
The Obigen Pharma EPS history
YEAREPSYoY
-2.57TWD+11.83%
-2.29TWD+12.41%
-2.04TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Obigen Pharma Stock analysis

What does Obigen Pharma do? Obigen Pharma Inc, listed on the Taiwan Stock Exchange under ticker 7876.TWO with ISIN TW0007876005, is a biotechnology company headquartered in Zhubei, Taiwan. The company operates within the Health Care sector and currently employs 57 full-time staff. Obigen Pharma is engaged in the research, development, manufacturing, and commercialization of novel botulinum toxin products. Its primary product, OBI-858, is a type A botulinum toxin formulation currently in phase II clinical trials in Taiwan for the treatment of frown lines in medical aesthetics. The company has established a complete supply chain for OBI-858 within Taiwan, covering research, development, and production. It collaborates with contract research organizations (CROs) to support the advancement of clinical trials for its drug candidates. The company's initial public offering (IPO) is scheduled for November 24, 2025. Obigen Pharma maintains a corporate website at www.obigenpharma.com for further information. Obigen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obigen Pharma stock

Earnings per Share (EPS) of Obigen Pharma is -2.57 TWD in 2024.

Earnings per Share (EPS) of Obigen Pharma changed from -2.29 TWD to -2.57 TWD, representing a 11.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Obigen Pharma since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Obigen Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Obigen Pharma